Table 2.
Clinical and genetic features of translocation and cyclin D (TC) molecular subgroups of multiple myeloma
|
Multiple trisomies
|
MRI positive
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TC group | Recurrent tx | Gene(s) at breakpoint | Dysregulated D cyclin | % of untreated patients | % of 30 relapsed patients | n | %* | PI greater than 0.2, %† | n | %‡ |
| 6p21 | 6p21 | CCND3 | D3 | 3 | 3 | 7 | 29 | 14 | 5 | 100 |
| 11q13 | 11q13 | CCND1 | D1 | 16 | 17 | 40 | 0 | 18 | 27 | 94∥ |
| D1 | none | none | D1 | 34∥ | 10∥ | 81 | 93§ | 5§ | 57 | 86 |
| D1 + D2 | none | none | D1 + D2 | 6∥ | 17∥ | 21 | 86§ | 43∥ | 13 | 100∥ |
| D2 | none | none | D2 | 17 | 20 | 45 | 40 | 16 | 27 | 67 |
| none | none | none | none | 2 | 3 | 6 | 33 | 17 | 4 | 100 |
| 4p16 | 4p16 | FGFR3/MMSET | D2 | 15 | 23 | 42 | 29§ | 21 | 28 | 57∥ |
| maf | 16q23, 20q11 | MAF, MAFB | D2 | 7 | 7 | 19 | 16§ | 32 | 11 | 55∥ |
| Total | – | – | – | 100 | 100 | 261 | 50 | 17 | 172 | 79 |
– indicates not applicable.
*
Percentage of samples within each TC group with gene expression profiling evidence for 3 or more trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19, or 21
†
Percentage of samples within each TC group with an expression PI greater then 0.2. There is a PI >0.2 in 67% of relapsed samples, and 10% of newly diagnosed MM (P < 10-13)
‡
Percentage of samples within each TC group from patients with lytic lesions on MRI. In pairwise comparisons, each of groups 11q13, D1, and D1 + D2 is significantly different (P < .05) from each of groups D2, 4p16, and maf
§
P < .001
∥
P < .05